Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Thai Hoa Tran, Sarah K Tasian
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor relapse-free survival despite risk-adapted multi-agent chemotherapy regimens. The advent of next-generation sequencing has unraveled the diversity of kinase-activating genetic drivers in Ph-like ALL that are potentially amenable to 'personalized' molecularly-targeted therapies. Based upon robust preclinical data and promising case series of clinical activity of tyrosine kinase inhibitor (TKI)-based treatment in adults and children with relevant genetic Ph-like ALL subtypes, several clinical trials have investigated the efficacy of JAK- or ABL-directed TKIs in CRLF2/JAK pathway-mutant or ABL-class Ph-like ALL, respectively...
April 24, 2024: Blood
#2
JOURNAL ARTICLE
Muhammad Awais, Riaz Ahmad, Nabeela Kausar, Ahmed Ibrahim Alzahrani, Nasser Alalwan, Anum Masood
Acute lymphoblastic leukemia (ALL) is a fatal blood disorder characterized by the excessive proliferation of immature white blood cells, originating in the bone marrow. An effective prognosis and treatment of ALL calls for its accurate and timely detection. Deep convolutional neural networks (CNNs) have shown promising results in digital pathology. However, they face challenges in classifying different subtypes of leukemia due to their subtle morphological differences. This study proposes an improved pipeline for binary detection and sub-type classification of ALL from blood smear images...
2024: Frontiers in artificial intelligence
#3
JOURNAL ARTICLE
Marta B Fernandes, A Margarida Gomes, Mariana L Oliveira, Joana Caldas, Paulo Lúcio, Rathana Kim, Aurélie Caye-Eude, Filomena Pereira, Aida B De Sousa, Alessia De Stefano, Matilde Y Follo, Maria V Soares, João F Lacerda, Joana Desterro, Hélène Cavé, Emmanuelle Clappier, Ximo Duarte, Patrícia Ribeiro, João T Barata
Not available.
April 24, 2024: Haematologica
#4
JOURNAL ARTICLE
Danielle Novetsky Friedman, Joanne F Chou, Jeanne M Clark, Chaya S Moskowitz, Jennifer S Ford, Gregory T Armstrong, Nidha Z Mubdi, Aaron McDonald, Paul C Nathan, Charles A Sklar, Lakshmi V Ramanathan, Leslie L Robison, Kevin C Oeffinger, Emily S Tonorezos
BACKGROUND: Obesity is prevalent in childhood cancer survivors and interacts with cancer treatments to potentiate risk for cardiovascular (CV) death. We tested a remote weight-loss intervention that was effective among adults with CV risk factors in a cohort of adult survivors of childhood acute lymphoblastic leukemia (ALL) with overweight/obesity. METHODS: In this phase 3 efficacy trial, survivors of ALL enrolled in the Childhood Cancer Survivor Study with body mass index (BMI)≥25 kg/m2 were randomized to a remotely-delivered weight-loss intervention versus self-directed weight loss, stratified by history of cranial radiotherapy (CRT)...
April 23, 2024: Cancer Epidemiology, Biomarkers & Prevention
#5
JOURNAL ARTICLE
Yao Li, Guan-Hua Hu, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Pan Suo, Yu Wang, Yi-Fei Cheng, Xiao-Jun Huang
BACKGROUND: Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia (ALL) has a high complete remission (CR) rate, but relapse and prolonged measurable residual disease remain serious problems. We sought to describe the CR rate measurable residual disease negative rate and address the results and safety of pediatric patients who underwent after receiving chimeric antigen receptor (CAR) specific for CD19 (CAR-19) followed by hematopoietic stem cell transplantation (HSCT) for the treatment of Ph-positive ALL...
April 23, 2024: Journal of Pediatric Hematology/oncology
#6
JOURNAL ARTICLE
Alexander Popov, Guenter Henze, Grigory Tsaur, Oleg Budanov, Julia Roumiantseva, Mikhail Belevtsev, Tatiana Verzhbitskaya, Liudmila Movchan, Svetlana Lagoyko, Liudmila Zharikova, Yulia Olshanskaya, Tatiana Riger, Alena Valochnik, Natalia Miakova, Dmitry Litvinov, Olga Khlebnikova, Olga Streneva, Elena Stolyarova, Natalia Ponomareva, Galina Novichkova, Olga Aleinikova, Larisa Fechina, Alexander Karachunskiy
BACKGROUND: Quantitative measurement of minimal residual disease (MRD) is the "gold standard" for estimating the response to therapy in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Nevertheless, the speed of the MRD response differs for different cytogenetic subgroups. Here we present results of MRD measurement in children with BCP-ALL, in terms of genetic subgroups with relation to clinically defined risk groups. METHODS: A total of 485 children with non-high-risk BCP-ALL with available cytogenetic data and MRD studied at the end-of-induction (EOI) by multicolor flow cytometry (MFC) were included...
April 2024: Cancer Medicine
#7
JOURNAL ARTICLE
S Korneeva M, A Batmanova N, R Panferova T, T Valiev T
Lymphoid tumors with testicular involvement in childhood are rare and heterogeneous. The disease may manifest with uni- or bilateral scrotal enlargement. Comprehensive examination includes evaluation of all lymph nodes involvement, as well as ultrasound examination, magnetic resonance imaging and positron emission tomography. A diagnosis is made on basis of morphological and immunohistochemical verification. Determination of lymphoid tumor variant and stage, is recommended to perform chemotherapy according to prognostic risk group, and, in some cases, transplantation of hematopoietic stem cells is required as consolidation therapy...
March 2024: Urologii︠a︡
#8
John Donald Marra, Eugenio Galli, Sabrina Giammarco, Elisabetta Metafuni, Gessica Minnella, Federica Fosso, Sara Marietti, Simona Sica, Federica Sorà, Patrizia Chiusolo
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease...
April 21, 2024: European Journal of Haematology
#9
JOURNAL ARTICLE
Nina Mogensen, Ulrika Kreicbergs, Birgitte Klug Albertsen, Päivi M Lähteenmäki, Mats Heyman, Arja Harila
BACKGROUND: The improved outcome of childhood acute lymphoblastic leukemia (ALL) over the last decades has increased the importance of assessing late effects and health-related quality of life (HRQoL), particularly when evaluating and comparing outcomes in clinical trials. This study aimed to assess HRQoL in children treated for ALL according to the NOPHO ALL2008 protocol. PROCEDURE: Children, aged 1 to less than 18 years at diagnosis, alive in first remission, and their parents, were asked to complete PedsQL 4...
April 21, 2024: Pediatric Blood & Cancer
#10
JOURNAL ARTICLE
Alex Hoover, Dave Watson, Paige Reimche, Lynn Tanner, Laura Gilchrist, Mike Finch, Yoav H Messinger, Lucie M Turcotte
OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and among the most common malignancies in young adults and requires a unique pattern of healthcare utilization including an acute/emergent presentation and an intensive initial 8 months of therapy followed by two years of outpatient treatment. The COVID-19 pandemic caused massive global disruptions in healthcare use and delivery. This report aims to examine the effects of the COVID-19 pandemic on the presentation, diagnosis and continued management of childhood and young adult ALL in regard to utilization and cost of care among commercially insured individuals in the United States...
April 22, 2024: BMC Research Notes
#11
JOURNAL ARTICLE
Jinglei Yu, Fengmei Song, Mingming Zhang, Pingnan Xiao, Jingjing Feng, Ruimin Hong, Yongxian Hu, He Huang, Guoqing Wei
BACKGROUND: Lysine [K] methyltransferase 2A (KMT2A, previously known as MLL) gene rearrangements are common in acute leukemias of various lineages and are associated with features such as chemotherapy resistance and rapid relapse. KMT2A::CBL is a rare fusion of unknown pathogenesis generated by a unique interstitial deletion of chromosome 11 that has been reported across a wide age range in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. The leukemogenic effect of the KMT2A::CBL rearrangement and its association with clinical prognosis have not been well clarified...
April 21, 2024: Molecular Biology Reports
#12
JOURNAL ARTICLE
Seon Young Kim, Ik-Chan Song, Jimyung Kim, Gye Cheol Kwon
We report a series of patients with CSF3R-mutant (CSF3Rmut ) atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL) or other hematologic malignancies. We included 25 patients: 5 aCML and 4 CNL CSF3Rmut patients; 1 aCML, 2 CNL, and 2 myelodysplastic/myeloproliferative neoplasm, not otherwise specified patients without CSF3R mutation; and 11 CSF3Rmut patients with other diseases [8 acute myeloid leukemia (AML), 1 chronic myelomonocytic leukemia (CMML), 1 myelodysplastic syndrome (MDS), and 1 acute lymphoblastic leukemia (ALL)]...
April 18, 2024: Annals of Diagnostic Pathology
#13
JOURNAL ARTICLE
Lihua Lu, Jiazheng Li, Yongzhi Zheng, Luting Luo, Yan Huang, Jianda Hu, Yanxin Chen
Solute carrier family 27 member 2 (SLC27A2) is involved in fatty acid metabolism in tumors and represents a prospective target for cancer therapy. However, the role and mechanism of action of SLC27A2 in acute lymphoblastic leukemia (ALL) remain unclear. In this study, we aimed to explore the intrinsic associations between SLC27A2 and ALL and evaluate the prognostic significance, biological functions, and correlation with immune infiltration. We used the transcriptome and clinical data from the TARGET dataset...
April 18, 2024: Translational Oncology
#14
JOURNAL ARTICLE
Alexandra E Kovach, Maximilian Wengyn, My H Vu, Andrew Doan, Gordana Raca, Deepa Bhojwani
BACKGROUND: Compared to other ethnicities, Hispanics/Latinos (H/L) have a high incidence of acute lymphoblastic leukemia (ALL), enrichment of unfavorable ALL genetic subtypes, and worse outcomes, even after correcting for socioeconomic factors. We previously demonstrated increased incidence of the high-risk genetic drivers IKZF1 deletion and IGH::CRLF2 rearrangement in H/L compared to non-H/L children with B-ALL. Here in an expanded pediatric cohort, we sought to identify novel genetic drivers and secondary genetic alterations in B-ALL associated with H/L ethnicity...
April 18, 2024: Pediatric Blood & Cancer
#15
JOURNAL ARTICLE
Laurent Phely, Luca Hensen, Christoph Faul, Christer Alexander Ruff, Dina Schneider, Wolfgang Andreas Bethge, Claudia Lengerke
No abstract text is available yet for this article.
April 18, 2024: JAMA Oncology
#16
JOURNAL ARTICLE
Alex Wk Leung, Jiaoyang Cai, Zhi Wan, Jiefen Qin, Yongjun Fang, Lirong Sun, Jiashi Zhu, Shaoyan Hu, Ningling Wang, Pan Gao, Xin Tian, Xiaofan Zhu, Fen Zhou, Xuedong Wu, Xiuli Ju, Xiaowen Zhai, Hua Jiang, Qun Hu, Changda Liang, Liangchun Yang, Hui Zhang, Jingyan Tang, Ju Gao, Ching-Hon Pui, Chi-Kong Li
Not available.
April 18, 2024: Haematologica
#17
JOURNAL ARTICLE
Joaquin Garcia-Solorio, Juan Carlos Núñez-Enriquez, Marco Jiménez-Olivares, Janet Flores-Lujano, Fernanda Flores-Espino, Carolina Molina-Garay, Alejandra Cervera, Diana Casique-Aguirre, José Gabriel Peñaloza-Gonzalez, Ma Del Rocío Baños-Lara, Ángel García-Soto, César Alejandro Galván-Díaz, Alberto Olaya-Vargas, Hilario Flores Aguilar, Minerva Mata-Rocha, Miguel Ángel Garrido-Hernández, Juan Carlos Solís-Poblano, Nuria Citlalli Luna-Silva, Lena Sarahi Cano-Cuapio, Pierre Mitchel Aristil-Chery, Fernando Herrera-Quezada, Karol Carrillo-Sanchez, Anallely Muñoz-Rivas, Luis Leonardo Flores-Lagunes, Elvia Cristina Mendoza-Caamal, Beatriz Eugenia Villegas-Torres, Vincent González-Osnaya, Elva Jiménez-Hernández, José Refugio Torres-Nava, Jorge Alfonso Martín-Trejo, María de Lourdes Gutiérrez-Rivera, Rosa Martha Espinosa-Elizondo, Laura Elizabeth Merino-Pasaye, María Luisa Pérez-Saldívar, Silvia Jiménez-Morales, Everardo Curiel-Quesada, Haydeé Rosas-Vargas, Juan Manuel Mejía-Arangure, Carmen Alaez-Verson
BACKGROUND: Recurrent genetic alterations contributing to leukemogenesis have been identified in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL), and some are useful for refining classification, prognosis, and treatment selection. IKZF1plus is a complex biomarker associated with a poor prognosis. It is characterized by IKZF1 deletion coexisting with PAX5 , CDKN2A/2B , or PAR1 region deletions. The mutational spectrum and clinical impact of these alterations have scarcely been explored in Mexican pediatric patients with B-ALL...
2024: Frontiers in Oncology
#18
Wei J Wang, Brandon T Gehris, Daniel Rivera, Sibel Ak, David Feng, Wei Wang, Zhihong Hu
Myeloperoxidase (MPO) is the most specific marker of the myeloid lineage, essential for diagnosing acute myeloid leukemia and mixed phenotype acute leukemia with myeloid components. In this regard, we present a unique case of B-acute lymphoblastic leukemia (B-ALL) with isolated MPO expression in bone marrow blasts detected by flow cytometry and immunohistochemistry, while peripheral blood blasts were negative for MPO expression. In this report, our discussion encompasses diagnostic pitfalls from a laboratory testing perspective in similar cases and includes a literature review...
April 2024: EJHaem
#19
JOURNAL ARTICLE
Sha Ma, Ying Wang, Kunming Qi, Wenyi Lu, Yuekun Qi, Jiang Cao, Mingshan Niu, Depeng Li, Wei Sang, Zhiling Yan, Feng Zhu, Hai Cheng, Zhenyu Li, Mingfeng Zhao, Kailin Xu
Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study of 67 patients with R/R B-ALL who received anti-CD19 CAR T-cell therapy, 41 (61.2%) patients received G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar duration of grade 3-4 neutropenia between the two groups...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
#20
JOURNAL ARTICLE
Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M Al Malki, Salman Otoukesh, Karamjeet Sandhu, Vaibhav Agrawal, Alex F Herrera, Leslie L Popplewell, Lucy Ghoda, Anthony Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor...
April 17, 2024: Leukemia & Lymphoma
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
